Are you having trouble sourcing BSA and BGG? – Proliant can help
As the world’s largest manufacturer of animal-derived proteins, we provide the highest levels of consistency, traceability, and quality in the market. With facilities in the U.S. and New Zealand, we have sustainable supply practices in place to help alleviate sourcing headaches, whether you’re in medical device manufacturing, in-vitro diagnostics, therapeutics, vaccine production, biopharmaceuticals, nutraceuticals, or any other number of life science research industries.
|
|
BioPharmGuy
We still plan to segment our service providers into more specific subcategories, but we would love some input on categorizations - the point is to make BioPharmGuy more useful for our site visitors.
Also, we have a new batch of shirts in the works - the light blue Gildan Softstyle were back in stock, baby! If you send us an exceptionally interesting/weird bit of biotech/science/health news and we end up using it in our newsletter there just might be a free shirt in it for you.
Companies Added & Removed
26 companies added this week, two removed.
Best New Name:
MitoRx Solutions
Stinkiest New Name:
Sampling Human
Zzzzzzz:
Biosimilar Solutions
Summary file of additions and removals available on our downloads page.
|
|
Good Deal
ICER has tentatively pronounced a $2.1M gene therapy to be a good deal. Only in America, right? Even if you know healthcare economics is a crazy science, still some serious sticker shock. The logic here is that the therapy can prevent decades of medical treatment while also savings lives.
Now don't get laid off, or you're gonna die.
American Dreamers
It’s a little weird for a company to come out and say they are “US-based” on their homepage. Usually they put their mailing address on the contact page and consider that good enough. In the case of iQure, they make this US-based claim, y et on LinkedIn they have five employees - two in Poland, two in Switzerland and one in England. Dream on, iQure.
Moleculin
It was time for a logo upgrade, so they went from this to this. New one has a cool spherical optical illusion. Doubt the kids can sketch it while they're bored in class, but luckily that's not a factor in biotech logo selection. 9/10
Lay Off the Pills
When you think of combining drugs and ASMR, plenty of weird stuff probably comes mind. Drug company Sanofi, however, wants you to think of magnetic stirrers and liquids pouring. That’s what you’ll hear on their new ASMR SoundCloud playlist. (Who was the ad wizard who decided on SoundCloud?) The latest track they dropped is a banger: “You Spin Me Round, Like a Centrifuge”.
NGL, this ASMR is giving BPG some PTSD from his time as an RA for an MD.
Can't Miss
It’s a long-running joke in the biotech industry that people swoon over preclinical data, then when clinical reality lands, everyone instantly moves on to the next amazingly awesome world-changing preclinical data. This cartoon sums up the preclinical data euphoria vs. clinical data reality quite well.
YouthBio
Funding Like It's 1999
This is some old school stuff here – enlightenVue announced a Series B round worth (pinky in corner of mouth) 1 Million dollars. Been a long time since we’ve seen a B round that small. A sign of things to come? Doubtful, but it's kind of refreshing to know some life science companies still have to scrape and prove themselves before getting 8 or 9-figure rounds.
Genovac
Hey, here’s a fun time zone fact - China and India each have one huge time zone. China is about 3400 miles wide, which also happens to be the distance between London and New York. Imagine London and New York being on the same time zone and you have the China time experience.
Psych
Every time we discover a publicly-traded company for the first time, it seems like they’re Canada-based and working on psychedelics. This week it was BetterLife Pharma.
We've said it before, but our opinion is there is no money to made in this space. At least for anyone except the executives who keep selling stock to retail day-traders. But when you think about it, most biotechs fails, so maybe this fleecing of retail traders is simply business as usual?
Ignoring all that, if you were a potential gambler, errr investor, wondering what this company’s market differentiation might be, here’s what they have to say:
“Meaning comes from execution plus adoption of concept-to-delivery solutions to gain traction with transparency, dependability, and authority leading to a widespread adoption for the unmet needs.”
Congratulations, subscriber, you are now dumber for having read that. It is unbelievable that a company whose stock is traded on multiple exchanges actually put that on their investor website. You may as well head to a casino and put it all on black.
|
|
Gamma, e-beam, or x-ray? Considerations for sterilization and bioburden control of medical devices and single-use systems
Today, new approaches to irradiation are required to close the gap between expected demand increases and available supply.
Get valuable insights into gamma, e-beam and x-ray sterilization modalities and regulatory considerations. Learn about comparatives studies by leading academic and trade organizations and the conclusions they draw on sterilization techniques.
|
|
First, Do You Validate?
As if the anguish and cost of chemotherapy weren’t enough, some cancer centers charge patients for parking. How much depends greatly on…availability of parking in the area.
A study of parking costs concluded that the median parking cost for an entire course of treatments was $0 for breast and head/neck cancer, and $210 for AML. This hides the highs and lows - maximum parking costs were $800/$665/$1680 over the treatment cycle, while most places were free.
Most of the highest charges were in very high cost of living places like NYC where no one should be driving a car anyways.
Moral: if you find yourself in a city where parking is expensive, try not to drive your car anywhere.
Hatch Closed
Former Senator Orrin Hatch died this week. In the drug industry, he is best remembered for co-sponsoring the Hatch-Waxman act which led to the generics industry as we know it. Prior to that legislation, generics companies were pretty much hamstrung by innovator drug companies. The legacy of the Act is that now, almost all small molecule therapies eventually get generic competition.
It would be nice for something like that to happen with biologics, but those are fundamentally more difficult to copy in the first place, so it's not as straightforward. But maybe some day...
Spirit in the Sky
This seems like the type of thing uncontacted Amazonian tribes might create religions around. Which is just great - the last thing we need is more people believing Elon Musk is some sort of god.
|
|
BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2022 Wilsonian LLC |
|
Check your website's analytics - we are likely one of your top referrers. You may be able to boost those referrals with a Premium Listing. Read more here: Promoted Listings.
Send us a message if you have questions or are interested.
|
|
|
|
|
|
|
|
